Downregulation of the Notch signaling pathway inhibits hepatocellular carcinoma cell invasion by inactivation of matrix metalloproteinase-2 and -9 and vascular endothelial growth factor

Zhou,Liang; Wang,De-Sheng; Li,Qing-Jun; Sun,Wei; Zhang,Yong; Dou,Ke-Feng

doi:10.3892/or.2012.1880

Downregulation of the Notch signaling pathway inhibits hepatocellular carcinoma cell invasion by inactivation of matrix metalloproteinase-2 and -9 and vascular endothelial growth factor

Authors:
- Liang Zhou
- De-Sheng Wang
- Qing-Jun Li
- Wei Sun
- Yong Zhang
- Ke-Feng Dou
View Affiliations

Affiliations: Department of General Surgery, The 155 Central Hospital of PLA, Kaifeng, He'nan 471000, P.R. China, Department of Hepatobiliary Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shannxi 710032, P.R. China
Published online on: June 20, 2012 https://doi.org/10.3892/or.2012.1880
Pages: 874-882

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies. The main cause of death in HCC patients is tumor progression with invasion and metastasis. However, the underlying mechanisms of HCC invasion and metastasis are still not fully understood. Some studies show that the Notch signaling pathway may participate in tumor invasion and metastasis. However, the mechanisms by which the Notch signaling pathway mediates tumor cell invasion, especially in hepatocellular carcinoma, are not yet known. In the current study, we investigated the anti-invasion effect of the downregulation of the Notch signaling pathway by DAPT in HCC cells. The Notch signaling pathway inhibitor could suppress invasion of HCC cells via the extracellular signal-regulated kinases 1 and 2 (ERK1/2) signaling pathways, resulting in the downregulation of matrix metalloproteinase-2 and -9 (MMP-2 and -9) and vascular endothelial growth factor (VEGF). These observations suggested that inhibition of the Notch signaling pathway by DAPT would be useful for devising novel preventive and therapeutic strategies targeting invasion of HCC.

View Figures

View References

1	Yang JD, Nakamura I and Roberts LR: The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol. 21:35–43. 2011. View Article : Google Scholar : PubMed/NCBI
2	Thomas MB and Zhu AX: Hepatocellular carcinoma: the need for progress. J Clin Oncol. 23:2892–2899. 2005. View Article : Google Scholar : PubMed/NCBI
3	Tang DJ, Dong SS, Ma NF, et al: Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma. Hepatology. 51:1255–1263. 2010. View Article : Google Scholar : PubMed/NCBI
4	Itoh Y and Nagase H: Matrix metalloproteinases in cancer. Essays Biochem. 38:21–36. 2002.PubMed/NCBI
5	Zeng ZS, Cohen AM and Guillem JG: Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis. 20:749–755. 1999. View Article : Google Scholar : PubMed/NCBI
6	Komatsu K, Nakanishi Y, Nemoto N, Hori T, Sawada T and Kobayashi M: Expression and quantitative analysis of matrix metalloproteinase-2 and -9 in human gliomas. Brain Tumor Pathol. 21:105–112. 2004. View Article : Google Scholar : PubMed/NCBI
7	Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4–6. 1990. View Article : Google Scholar : PubMed/NCBI
8	Joo YE, Sohn YH, Lee WS, et al: Expression of vascular endothelial growth factor and p53 in pancreatic carcinomas. Korean J Intern Med. 17:153–159. 2002.PubMed/NCBI
9	Zeng H, Datta K, Neid M, Li J, Parangi S and Mukhopadhyay D: Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line. Biochem Biophys Res Commun. 302:46–55. 2003. View Article : Google Scholar : PubMed/NCBI
10	Artavanis-Tsakonas S, Rand MD and Lake RJ: Notch signaling: cell fate control and signal integration in development. Science. 284:770–776. 1999. View Article : Google Scholar : PubMed/NCBI
11	Miele L and Osborne B: Arbiter of differentiation and death: Notch signaling meets apoptosis. J Cell Physiol. 181:393–409. 1999. View Article : Google Scholar : PubMed/NCBI
12	Allenspach EJ, Maillard I, Aster JC and Pear WS: Notch signaling in cancer. Cancer Biol Ther. 1:466–476. 2002. View Article : Google Scholar
13	Nickoloff BJ, Osborne BA and Miele L: Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene. 22:6598–6608. 2003. View Article : Google Scholar : PubMed/NCBI
14	Leong KG and Karsan A: Recent insights into the role of Notch signaling in tumorigenesis. Blood. 107:2223–2233. 2006. View Article : Google Scholar : PubMed/NCBI
15	Radtke F and Raj K: The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer. 3:756–767. 2003. View Article : Google Scholar : PubMed/NCBI
16	Zweidler-McKay PA, He Y, Xu L, et al: Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies. Blood. 106:3898–3906. 2005. View Article : Google Scholar : PubMed/NCBI
17	Kunnimalaiyaan M and Chen H: Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist. 12:535–542. 2007. View Article : Google Scholar : PubMed/NCBI
18	Proweller A, Tu L, Lepore JJ, et al: Impaired notch signaling promotes de novo squamous cell carcinoma formation. Cancer Res. 66:7438–7444. 2006. View Article : Google Scholar : PubMed/NCBI
19	Seiffert D, Bradley JD, Rominger CM, et al: Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors. J Biol Chem. 275:34086–34091. 2000. View Article : Google Scholar : PubMed/NCBI
20	Tung-Ping Poon R, Fan ST and Wong J: Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 232:10–24. 2000.PubMed/NCBI
21	Sahlgren C, Gustafsson MV, Jin S, Poellinger L and Lendahl U: Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci USA. 105:6392–6397. 2008. View Article : Google Scholar : PubMed/NCBI
22	Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y and Sarkar FH: Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 66:2778–2784. 2006. View Article : Google Scholar
23	Fidler IJ: The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 3:453–458. 2003.
24	Weiss L: Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer Metastasis Rev. 19:193–383. 2000. View Article : Google Scholar : PubMed/NCBI
25	Vihinen P and Kahari VM: Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer. 99:157–166. 2002. View Article : Google Scholar : PubMed/NCBI
26	Curran S and Murray GI: Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. 36:1621–1630. 2000. View Article : Google Scholar : PubMed/NCBI
27	John A and Tuszynski G: The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res. 7:14–23. 2001. View Article : Google Scholar : PubMed/NCBI
28	Cockett MI, Murphy G, Birch ML, et al: Matrix metalloproteinases and metastatic cancer. Biochem Soc Symp. 63:295–313. 1998.PubMed/NCBI
29	Bianco FJ Jr, Gervasi DC, Tiguert R, et al: Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade. Clin Cancer Res. 4:3011–3016. 1998.PubMed/NCBI
30	Murphy AN, Unsworth EJ and Stetler-Stevenson WG: Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol. 157:351–358. 1993. View Article : Google Scholar : PubMed/NCBI
31	Wey JS, Fan F, Gray MJ, et al: Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer. 104:427–438. 2005. View Article : Google Scholar : PubMed/NCBI
32	Takahashi Y, Kitadai Y, Bucana CD, Cleary KR and Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 55:3964–3968. 1995.PubMed/NCBI
33	Balint K, Xiao M, Pinnix CC, et al: Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest. 115:3166–3176. 2005. View Article : Google Scholar : PubMed/NCBI
34	Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H and Dorken B: Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood. 99:3398–3403. 2002. View Article : Google Scholar : PubMed/NCBI
35	Buchler P, Gazdhar A, Schubert M, et al: The Notch signaling pathway is related to neurovascular progression of pancreatic cancer. Ann Surg. 242:791–801. 2005. View Article : Google Scholar : PubMed/NCBI
36	Yu B, Wei J, Qian X, Lei D, Ma Q and Liu Y: Notch1 signaling pathway participates in cancer invasion by regulating MMPs in lingual squamous cell carcinoma. Oncol Rep. 27:547–552. 2012.PubMed/NCBI
37	Wang J, Fu L, Gu F and Ma Y: Notch1 is involved in migration and invasion of human breast cancer cells. Oncol Rep. 26:1295–1303. 2011.PubMed/NCBI
38	Delbosc S, Glorian M, Le Port AS, Bereziat G, Andreani M and Limon I: The benefit of docosahexanoic acid on the migration of vascular smooth muscle cells is partially dependent on Notch regulation of MMP-2/-9. Am J Pathol. 172:1430–1440. 2008. View Article : Google Scholar : PubMed/NCBI
39	Xiong HQ, Abbruzzese JL, Lin E, Wang L, Zheng L and Xie K: NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. Int J Cancer. 108:181–188. 2004. View Article : Google Scholar : PubMed/NCBI
40	Funahashi Y, Shawber CJ, Sharma A, Kanamaru E, Choi YK and Kitajewski J: Notch modulates VEGF action in endothelial cells by inducing Matrix Metalloprotease activity. Vasc Cell. 3:22011. View Article : Google Scholar : PubMed/NCBI
41	Chan-Hui PY and Weaver R: Human mitogen-activated protein kinase kinase kinase mediates the stress-induced activation of mitogen-activated protein kinase cascades. Biochem J. 336:599–609. 1998.PubMed/NCBI
42	Trusolino L and Comoglio PM: Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer. 2:289–300. 2002. View Article : Google Scholar : PubMed/NCBI
43	Chen PN, Hsieh YS, Chiou HL and Chu SC: Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chem Biol Interact. 156:141–150. 2005. View Article : Google Scholar : PubMed/NCBI
44	Arai K, Lee SR and Lo EH: Essential role for ERK mitogen-activated protein kinase in matrix metalloproteinase-9 regulation in rat cortical astrocytes. Glia. 43:254–264. 2003. View Article : Google Scholar : PubMed/NCBI
45	Zeigler ME, Chi Y, Schmidt T and Varani J: Role of ERK and JNK pathways in regulating cell motility and matrix metalloproteinase 9 production in growth factor-stimulated human epidermal keratinocytes. J Cell Physiol. 180:271–284. 1999. View Article : Google Scholar : PubMed/NCBI
46	Giuliani N, Lunghi P, Morandi F, et al: Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Leukemia. 18:628–635. 2004. View Article : Google Scholar : PubMed/NCBI
47	Okajima E and Thorgeirsson UP: Different regulation of vascular endothelial growth factor expression by the ERK and p38 kinase pathways in v-ras, v-raf, and v-myc transformed cells. Biochem Biophys Res Commun. 270:108–111. 2000. View Article : Google Scholar : PubMed/NCBI
48	Wang Z, Li Y, Banerjee S and Sarkar FH: Exploitation of the Notch signaling pathway as a novel target for cancer therapy. Anticancer Res. 28:3621–3630. 2008.PubMed/NCBI